Table 4.

Proportional Hazard Model for All-cause Mortality Through Week 48 Post–hematopoietic Cell Transplant

Factors	Multivariable HR (95% CI)	P Value
Letermovir vs placebo with CS-CMVi	0.45 (0.21–1.00)	.05
Letermovir vs placebo without CS-CMVi	1.05 (0.61–1.81)	.85
CS-CMVi through week 24 (time dependent)	2.05 (1.09–3.88)	.03
Acute GVHD grades II–IV (time dependent)	2.58 (1.69–3.92)	<.001
Age (by 10-year increase)	1.29 (1.10–1.52)	.002
Baseline CMV risk of CMV reactivation (high vs low)	1.70 (1.13–2.57)	.01

Abbreviations: CI, confidence interval; CMV, cytomegalovirus; CS-CMVi, clinically significant cytomegalovirus infection; GVHD, graft-versus-host disease; HCT, hematopoietic stem-cell transplantation; HR, hazard ratio.